Onconetix Inc. stock surged 23.65% in after-hours trading following positive clinical validation of its prostate cancer blood test, Proclarix. Two new peer-reviewed studies from Denmark showed Proclarix can reduce unnecessary biopsies and overdiagnosis, outperforming existing tests. The company also launched a U.S. validation trial with Labcorp to support a domestic test launch. Despite recent financial challenges and a 99% stock drop over the past year, this clinical progress may improve investor sentiment and future prospects.
In the first quarter of 2026, hedge funds dramatically increased their investments in semiconductor stocks, pushing sector exposure to a record 19% of global hedge fund portfolios, more than doubling since the start of the year. Major investors like ...
Oriental Rise Holdings Ltd. saw its stock price surge 18.84% after hours following a board-approved reverse stock split at a 1-for-4 ratio. The reverse split, approved by shareholders, reduces the number of outstanding shares and increases the per-sh...
U-BX Technology's stock fell 15.6% in after-hours trading following the announcement of a 1-for-25 reverse stock split effective Friday. The move will reduce the number of outstanding shares significantly to maintain Nasdaq listing compliance. The co...
LexinFintech Holdings Ltd., a leading personal financial service provider in China, announced it will report its unaudited financial results for Q1 2026 on May 25 before the U.S. market opens. The company will hold a conference call for investors and...
Anaveon, a Swiss biotech firm focused on precision biologics for autoimmune diseases, announced the appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer. These new executives bring extensive expertise in im...
